More on Placebo Response

Sir: The article by Stein et al. on placebo response may, due to the data available, be missing much of the "forest" in the United States. Larger issues include the following:

1. There are many fewer untreated depressed patients in the community today than even 5 to 10 years ago, thanks to reduced stigma regarding depression, widespread prescribing by family practitioners and other physicians of the newer antidepressants (which are so relatively safe and easy to use), and the low cost of generic antidepressants. In my first drug company–funded depression study, I easily recruited 45 patients, spending less than $5000 on newspaper ads. Currently, $5000 for ads near Princeton might yield 2 or 3 patients.

2. In the "old days," studies typically involved fewer investigators, with each investigator entering more patients. With the considerable (and increasing) time required to prepare for a study (e.g., being certified on ratings), a study is not really worth doing if one can enter only a few patients. By the time investigators have prepared their staff to conduct a study, they are strongly motivated to enter as many patients as possible quickly, especially with competitive enrollment and the prospect of a study ending early if other sites recruit quickly. Advertising funds are also often limited. A recent study (J.A.M., unpublished data, 2002–2003) had a high placebo response rate and increased recruitment later in the study when it seemed that some of the sites were not going to have time enough to recruit the originally requested number of patients; drug-placebo differences were less in the group of patients that was entered at this time, presumably due to excessive investigator motivation to enter patients quickly. Rather than the many machinations companies have gone through to try to minimize placebo response, such as increased training and blinded raters, I believe that a more productive approach would be to have fewer sites, to guarantee sites that they would have a certain number of months to enter the requested number of patients without worrying that the study would end earlier, and to have a very liberal advertising budget once the sites have been selected. In addition, exclusion criteria in protocols are sometimes excessive, unnecessarily excluding patients who are ideal from other perspectives (e.g., a patient with prior depressive episodes who has responded well to medications).

One approach, if approved by institutional review boards, would be to pay patients who are known to be medication responsive (and who are on maintenance antidepressants) to discontinue medication, become depressed, and participate in a study. Even at $10,000 per patient, drug companies would be ahead financially; a much smaller N would be needed, using this ideal population. The ethics may be reasonable (for non-suicidal patients), especially given the peculiar (and relatively recent) belief that it is unethical for corporations to focus on anything other than shareholder profit. Why shouldn’t depressed, medication-responsive patients, who can reliably demonstrate and discern a medication effect, also profit?

Dr. Mattes reports no financial affiliation or other relationship relevant to the subject of this letter.

REFERENCES


Jeffrey Allan Mattes, M.D.
Psychopharmacology Research Association of Princeton
Princeton, New Jersey

Dr. Stein and Colleagues Reply

Sir: We are pleased that our article on the placebo response in the escitalopram randomized controlled trials has generated some discussion.

Dr. Mattes’s first point is that there are fewer untreated depressed patients in the community than there used to be. Epidemiologic data certainly indicate that over the past decade or more, there has been an increase in treatment rate in patients with a mental disorder in the United States. Nevertheless, we would also note another conclusion from such work: most patients with a mental disorder do not receive treatment.

In his second point, Dr. Mattes suggests that pressure to recruit may result in an increased placebo response rate and that addressing this issue (e.g., with noncompetitive recruitment and better advertising budgets) is more useful than other approaches focused on reducing the placebo response (e.g., more training and use of “blinded” raters). Certainly, multiple factors affect the placebo response. Nevertheless, our view is that different approaches need to be taken to maximize medication-placebo differences and that the data about which methods are best are not yet conclusive.

Finally, Dr. Mattes suggests that depressed patients who previously responded to medication and are on maintenance treatment should be allowed to relapse and be paid to participate in clinical trials sponsored by the pharmaceutical industry. This proposal strikes us as unethical (patients would effectively be paid to become ill), and we are not convinced the data would be meaningful (payment may result in distortion of symptoms, and the sample is unlikely to be a representative one).

We take the opportunity of a discussion about recruitment into clinical trials to reiterate a point made by Chalmers and Lindley that there is a need to increase awareness of the “inclusion benefit” for participants in clinical trials. Many conceptualize trial participants as being “human guinea pigs.” In fact, routine clinical care is often experimental, and treatment in the context of a trial can have excellent outcomes. Indeed, a systematic review of studies comparing patients treated in the context of controlled trials with apparently similar patients treated outside trials showed that, on average, the prognoses of the former are better than those of the latter.

The study referred to in this letter was supported by H. Lundbeck A/S. Dr. Stein has received research grants and/or consultancy honoraria from AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, and Wyeth. Dr. Baldwin has been a consultant for Asahi, Cephalon, Eli Lilly, GlaxoSmithKline, Lundbeck, Organon, Pfizer, Pharmacia, Pierre Fabre, Roche, Servier, and Werth; has received grant/research support from Cephalon, Eli Lilly, GlaxoSmithKline, Lundbeck, Organon, Pfizer, Roche, and Wyeth; has received honoraria from Cephalon, Eli Lilly, GlaxoSmithKline, Lundbeck, Organon, Pfizer, Roche, and Wyeth; has received honoraria from Cephalon, Eli Lilly, GlaxoSmithKline, Lundbeck.
Hyperactivity Disorder: A Case Report

Corpus Callosum Dysplasia in Adult Attention-Deficit/Hyperactivity Disorder: A Case Report

Sir: Primary attention-deficit/hyperactivity disorder (ADHD) is generally believed to be a disorder of adrenergic and dopaminergic neurotransmission, but there are also secondary forms of ADHD, for example, in patients with epilepsy or Tourette's disorder.

We report on an adult patient who presented with classical primary ADHD symptoms that began in early childhood in association with moderate dyslexia. Treatment with psychostimulant medication did not yield positive effects, and even worsened the patient's impulsivity and irritability. Routine magnetic resonance imaging (MRI) scanning mainly showed a severe form of partial agenesis and dysplasia of the corpus callosum. Electroencephalogram (EEG) and laboratory examination findings were essentially within normal limits.

This is the first published report of an association between agenesis of the corpus callosum and adult ADHD. There are, however, publications on this association in children. Clinicians should be aware of this association because afflicted patients might not respond or even respond adversely to psychostimulant medication. This case illustrates the need for thorough investigations of ADHD patients, including brain imaging. We discuss the possible role of the corpus callosum in the pathogenesis of ADHD and therapeutic implications.

ADHD is defined as the continuous presence of certain core symptoms beginning in early childhood. While hyperactivity often fades away during adolescence, other core symptoms such as attention deficit, impulsivity, and emotional instability often persist in adulthood and cause many problems in occupational, interpersonal, and social life.

The etiology of ADHD is still poorly understood. The primary form of ADHD has a high genetic loading with a positive family history. However, there are also secondary forms of ADHD in the context of other neuropsychiatric disorders such as epilepsy, chorea minor (Sydenham’s chorea), or Gilles de la Tourette disorder.

Particularly in primary ADHD, there is much evidence that suggests a crucial pathogenic role of systemic adrenergic and dopaminergic dysfunctions (for review, see references 8 and 9). Imaging studies support the hypothesis that this central pathophysiology during development leads to morphometric and functional brain abnormalities that correlate with the neuropsychological and psychiatric symptoms of ADHD. The brain regions that are most commonly viewed as abnormal in ADHD include the prefrontal lobe, the basal ganglia, and the cerebellum, and there is also growing evidence of corpus callosum abnormalities.

We present a case of an adult patient with classical symptoms of ADHD and moderate dyslexia who suffers from a severe form of partial agenesis and dysplasia of the corpus callosum.

Case report. Mr. A, a 32-year-old white male construction worker, presented to our ADHD outpatient clinic in 2005 complaining about symptoms of motor hyperactivity and inner agitation, severe inattention, extreme impulsivity (e.g., throwing objects around due to anger), and emotional instability since childhood.

His school reports reflected this history and were confirmed by his mother. The patient was diagnosed with moderate dyslexia in the fourth grade. The mother recalled a long and difficult delivery; however, no birth complications were documented. Also, there was no history of other organic brain disease due to pregnancy complications, and there were no infective or inflammatory brain diseases or childhood seizures. Moreover, neither his 2 siblings nor other relatives of first or second degree had ADHD symptoms, dyslexia, or other neuropsychiatric disorders.

The clinical diagnosis of persisting adult ADHD was made based on careful psychiatric and psychometric investigations using the short version of the Wender Utah Rating Scale (WURS-k; German version), which includes 25 items scored on a 5-point Likert scale (0–4, “not at all” to “severe”). Additionally, we used the ADHD-Checklist (ADHD-CL), which includes 18 items scored on a 3-point Likert-scale corresponding to the diagnostic criteria of DSM-IV (0–2, “not at all” to “severe”). His WURS-k score was 66, and his ADHD-CL score was 24. Also, histories were taken from relatives and caregivers. Findings of other routine medical, EEG, and laboratory investigations were essentially within normal limits (slightly decreased white blood cells: 3500/µL; normal range = 4300–10,000/µL). The patient’s neurologic examination indicated no focal deficits.

The patient had not been previously treated with any medication. His parents had merely sought educational advice. Therefore, we prescribed methylphenidate, a first-line medication. Taking into consideration its effects and adverse events, we carefully titrated it to 1.0 mg/kg (65 mg daily) for 12 weeks. This resulted in slight gastrointestinal side effects but no clinical benefit. On the contrary, impulsivity and irritability even worsened as reported by the patient, his family members, and his partner.

A T1-weighted MRI study that was primarily performed for research purposes revealed a severe form of dysplasia of the
corpus callosum in combination with a cystic abnormality in
the area of the pituitary gland. Subsequent elaborated T1- and
T2-weighted MRI studies confirmed the radiological diagnosis
of agenesis and dysplasia of the corpus callosum with a cystic
alteration of the anterior splenium and hypoplasia of the poste-
rior splenium (see Figure 1). Only the anterior portion of the
cingulate gyrus was present, and the circular cystic structure of
the pituitary gland was radiologically assessed as a hemorrhage
or a protein-rich cyst. There was no evidence of inflammation
or proliferating abnormalities in that area.

Subsequent extensive neuroendocrinological studies showed
essentially normal findings (findings were within normal
limits for thyroid-stimulating hormone, luteinizing hormone,
follicle-stimulating hormone, testosterone, prolactin, insulin-
like growth factor, dehydroepiandrosterone, slightly increased
adrenocorticotropic hormone [ACTH, 70 pg/mL; normal range,
9–52 pg/mL], and cortisol [624 nmol/L; normal range, 171–536
nmol/L]. The slightly increased concentrations of ACTH and
cortisol were assessed to be noncritical by our endocrinological
experts. A follow-up MRI 6 months later revealed no structural
difference compared to the baseline MRI. The patient refused to
take any other medication, but did receive psychiatric therapy
including behavioral therapy.

In summary, this is the first published case of an adult pa-
tient with clinical presentation of classical ADHD and moderate
dyslexia along with a severe partial agenesis and dysplasia of
the corpus callosum in association with a cystic lesion in the
pituitary and an abnormality of the posterior cingulate. Since
the slightly elevated concentrations of ACTH and cortisol were
assessed to be noncritical by our endocrinological experts, the
agenesis and dysplasia of the corpus callosum and the posterior
cingulate are the prevailing pathologic brain findings in this pa-
tient. However, we cannot exclude that, in spite of essentially
normal functional parameters of the pituitary gland, dysfunction
of this neuroendocrinological system possibly linked to the cy-
stic lesion might play a role in the pathogenesis of the ADHD
symptoms in this patient. Nevertheless, for the reasons men-
tioned in the discussion that follows, we want to concentrate on
the possible pathogenetic role of the corpus callosum and the
posterior cingulate in this patient.

The corpus callosum is the major commissure connecting
the cerebral hemispheres. In ADHD, the corpus callosum—
particularly the splenium—is one of the regions most frequently
reported as abnormally reduced in volume.12,16,17

In animal models, an association between total agenesis of
the corpus callosum and ADHD-like symptoms has been re-
ported.18 However, we found few cases of children with total
or partial agenesis of the corpus callosum associated with
ADHD. An early (1980) study20 describes the case of a girl with
agenesis of the corpus callosum and “minimal brain dysfunc-
tion,” a concept used to describe ADHD at that time, as well as
mild dyslexia. Parraga and coworkers20 also reported 2 cases
of patients with attention deficits associated with other psy-
chiatric and behavioral problems: 1 boy with total agenesis and
colpocephaly (abnormal enlargement of the occipital horns) and
1 girl with partial agenesis of the corpus callosum, predomi-
nantly of the rostrum and the body. The boy with the total agen-
esis of the corpus callosum also suffered from complex partial
seizures; the girl showed slightly abnormal EEG findings.
There is also 1 case report of a boy with classical ADHD and
oppositional defiant disorder in whom MRI revealed a total
agenesis of the corpus callosum.21 In that case, medical treat-
ment with methylphenidate brought about improvement of the
attentional problems, whereas the impulse-control disturbance
remained unchanged. The latter did decrease with behavioral
treatment and neuroleptic medication with sulpiride.

The question arises whether our case should be nosologi-
cally classified as a form of primary ADHD and moderate
dyslexia with additional incidental brain abnormalities, or alter-
atively as a secondary form of ADHD due to partial agenesis
dysplasia of the corpus callosum (i.e., as a kind of organic
psychiatric disorder). In addition to genetic factors, low birth
weight (<2500 g), premature birth, and complications during
pregnancy and neonatal life have been identified as risk factors
for ADHD.4 Interestingly, in very low–birth-weight adolescents
(<1500 g), a thinning and white matter reduction of the corpus
callosum was also found and was associated with severity of
ADHD symptoms.22 In this context, it is striking that a large
follow-up study in young children with prenatally diagnosed
agenesis of the corpus callosum revealed persisting attention
problems and irritability despite essentially normal cognitive
functioning.23

Besides the potential role of the corpus callosum in the
pathogenesis of ADHD symptomatology, the lesion of the cin-
gulate cortex must be considered. In ADHD, there are several
reports of volume reductions24 and altered functions of the ante-
rior cingulate cortex as well as of its involvement in medical
effects of methylphenidate.6,27 In our case, however, the poste-
rior portion was absent. The posterior cingulate receives affe-
rents from the thalamus and the hippocampus. However, little is
known about a specific role of the posterior cingulate in ADHD
symptomatology. One study28 revealed abnormal morphometric
findings of the left posterior cingulate associated with volume
decrease of the anterior and middle cingulated cortex in chil-
dren and adolescents with ADHD, suggesting that the posterior
cingulate may also play a potential role in the pathogenesis of
ADHD, particularly in emotional processing, which has been
reported in anxiety disorders29 and schizophrenia.30 With regard
to the co-occurring dyslexia, it is interesting that in patients
with traumatic brain injuries a dysfunction of the posterior cin-
gulate was associated with an impairment of learning and
memory.31 Nevertheless, the precise function of the posterior
cingulate is still poorly understood.

There are a few points in the history and the clinical course
of this case that might have hinted at an organic or secondary
form of ADHD. First, there was no positive family history. Sec-
ond, though the patient also complained about dyslexia, which
is often combined with ADHD,32 and though both disorders
might be explained, at least in part, by genetic factors,33 dys-
exia in the context of ADHD might still be an indicator of a

Figure 1. Magnetic Resonance Image Showing Severe Partial
Agenesis and Dysplasia of the Corpus Callosum

*Arrow indicates circular cystic structure of the pituitary gland, which
was radiologically assessed as a likely hemorrhage or protein-rich
cyst.
secondary pathogenesis possibly pointing to a more widespread brain pathology in terms of corticocortical disconnectivity and dysfunction of the corpus callosum. This hypothesis is supported by the fact that severe corpus callosum volume reduction has been associated with dyslexia. 34–39 Third, in a recently published large survey, persons with agenesis of the corpus callosum had a greater risk for neurologic deficits and different behavioral problems compared to their siblings. 40

Finally, the patient did not benefit from stimulant treatment. In contrast, the symptoms even worsened. This finding is in line with one study that revealed smaller splenium areas of the corpus callosum in children with ADHD who did not respond well to stimulants compared to stimulant responders. 34

It has been found that children with ADHD have disturbed transcallosally mediated inhibition. This finding indicates a probable dysbalance between excitatory and inhibitory interneuronal activities, 41–45 which could be improved after medication with methylphenidate. 46 Thus, the corpus callosum might be an important target structure of methylphenidate effects. In summary, we feel that our patient should be classified as suffering from a secondary form of ADHD in spite of the classical psychopathologic presentation. The case highlights several important clinical points. First, it illustrates the need for thorough baseline diagnostics. Routine MRI or computed tomography scans are currently not recommended in many countries. 47 However, at least in those cases with insufficient response to medical treatment or with unusual adverse events, further cerebral imaging studies should be performed. Second, this case supports the hypothesis that dyslexia in the context of ADHD symptoms might hint at a secondary pathogenesis such as cortical disconnectivity and corpus callosum dysfunction. Finally, clinicians should be aware of this malformation because it might predict poor or even adverse response to psychostimulant treatment in ADHD.

The study was conducted without any intramural financial support. The authors report no financial affiliation or other relationship relevant to the subject of this letter.

REFERENCES

4. Dunn DW, Kronenberger WG. Childhood epilepsy, attention problems, and ADHD: review and practical considerations. Semin Pediatr Neurol 2005;12:222–228
We report a patient with schizophrenia whose cognitive function-impairment in executive functions. Ms. A performed poorly on tests for executive functions, namely, the Trail-Making test parts A and B and the Stroop color-word interference test (Trail-Making test part A = 86 seconds and part B = 240 seconds, with 14 cognitive set–learning errors; Stroop interference score = 187 seconds and difference score = 121 seconds).

Since Ms. A did not have attention and concentration deficits before the onset of schizophrenia, the possibility of attention deficit disorder was ruled out and these deficits were diagnosed as part of cognitive deterioration in schizophrenia. She was started on atomoxetine, 18 mg/day; risperidone treatment was also continued. Repeat assessments using the same tests revealed substantial improvement in performance after 5 days (Stroop interference score = 100 seconds and difference score = 36 seconds; Trail-Making test part A = 70 seconds and part B = 143 seconds, with 5 cognitive set–learning errors).

During follow-up after 1 year, at which time she was still receiving atomoxetine and risperidone, Ms. A continued to exhibit no psychotic symptoms. She reported slight reduction in appetite but no other side effects. The improvements in cognitive deficits persisted, and she had become independent in her activities of daily living and could keep track of lengthy conversations. Also, she was employed as a computer operator with improved occupational functioning. These improvements were ascertained by reliable corroborative information obtained from 2 adult first-degree relatives.

To the best of our knowledge, this is the first report of reduction in cognitive deficits in schizophrenia after treatment with atomoxetine. Though the rapidity of improvement might suggest the possibility of a placebo effect, such an effect is unlikely because (1) in an earlier study examining attention-deficit/hyperactivity disorder, atomoxetine (18 mg/day) significantly reduced attention deficits as early as within 1 week and (2) persistent functional improvements were seen at 1-year follow-up (a placebo effect is less likely to persist).

Atomoxetine, though it is a norepinephrine reuptake inhibitor, increases extracellular dopamine concentration in prefrontal cortex without any such effect in striatum/nucleus accumbens. This is because dopamine is taken up nonselectively by norepinephrine transporters in the prefrontal cortex. Atomoxetine may act by these indirect mechanisms to enhance dopamine D1 receptor activity in the prefrontal cortex. Atomoxetine is advantageous in comparison to other stimulants because of its longer duration of action, lower risk of rebound symptoms, lower risk of induction of tics or psychosis, and lack of abuse potential. Its proposed therapeutic role in schizophrenia needs systematic evaluation in controlled trials.

The authors report no financial affiliation or relationship relevant to the subject of this letter.

REFERENCES


TREATMENT OF COGNITIVE DEFICITS IN SCHIZOPHRENIA WITH ATOMOXETINE: A CASE REPORT

SIR: Schizophrenia patients have deficits in attention, concentration, and information processing that result in significant functional impairment. Atomoxetine, a novel cognitive enhancer that can reduce executive function deficits, has been postulated to potentially treat these deficits in schizophrenia. We report a patient with schizophrenia whose cognitive functioning improved after adjunctive treatment with atomoxetine.

Case report. Ms. A, a 36-year-old woman with a diagnosis of paranoid schizophrenia (DSM-IV), presented in 2006 with complaints of significant disturbances in attention and concentration leading to substantial occupational dysfunction, inability to follow lengthy conversations, and difficulties in other activities of daily living. Her psychotic symptoms had been well controlled with risperidone (2 mg/day) over the previous 5 years. On examination, Ms. A had no delusions or hallucinations and was euthymic, and her judgment and abstraction were intact. Results of liver and thyroid function tests were within normal limits. Neuropsychological assessments revealed significant


Alexandra Philiopens, M.D.
Ludwig Tébartz van Elst, M.D.
Evgéniy Perlov, M.D.
Díeter Ebert, M.D.
Bernd Hesslinger, M.D.
ADHD Research Group & Section for Experimental Neuropsychiatry
Department of Psychiatry and Psychotherapy
University Clinic of Freiburg
Freiburg, Germany

LETTERS TO THE EDITOR

1988


A Case of Olanzapine-Induced Gestational Diabetes Mellitus in the Absence of Weight Gain

Sir: Second-generation antipsychotics have been implicated in the development of obesity, diabetes mellitus, and insulin resistance. Pregnancy increases the risk for insulin resistance, sometimes resulting in gestational diabetes mellitus. We describe a case of a woman with bipolar disorder who developed gestational diabetes in the absence of significant weight gain while treated with olanzapine during 2 pregnancies.

Case report. Ms. A, a 38-year-old nulliparous Japanese woman with a history of bipolar disorder type II based on DSM-IV criteria, presented to the outpatient psychiatry clinic in 2004 for prenatal counseling. She denied personal or family history of diabetes. Her symptoms were controlled with lithium 900 mg, olanzapine 2.5 mg, and lamotrigine 350 mg daily. Conception occurred 3 months later.

Lithium was discontinued at 5 weeks’ gestation. Lamotrigine 350 mg daily was continued throughout pregnancy and postpartum. At week 24, olanzapine was increased from 2.5 to 5.0 mg/day due to hypompanic symptoms.

A glucola* at 4 weeks’ gestation (122 mg/dL) and a fasting blood glucose level at 16 weeks (87 mg/dL) were within normal limits. An oral glucose tolerance test (OGTT) at 25 weeks revealed hyperglycemia postgestation at 1 hour (182 mg/dL) and 2 hours (162 mg/dL). Gestational diabetes was diagnosed and managed via dietary changes.

Full-term vaginal delivery occurred at 40 weeks. The infant’s weight was 3450 grams (7.6 lb) and Apgar scores of 9/9 were within normal limits. The patient’s prepartum body mass index (BMI) was 20 kg/m², both within the normal range.

In the first year postpartum, the olanzapine dose of 5 mg/day was steadily increased, due to hypompanic symptoms, up to 15 mg/day. The patient reported elevated fasting blood glucose levels from finger sticks ranging from 95 mg/dL to 112 mg/dL†; however, fasting serum blood glucose levels were within normal limits. At 11 months postpartum, elevated triglycerides (185 mg/dL) and a low high-density lipoprotein level (35 mg/dL) were noted, with a triglyceride/high-density lipoprotein ratio of 5.2, suggestive of insulin resistance.1

Twenty months postpartum, the patient became pregnant while treated with lamotrigine 400 mg/day and olanzapine 15 mg/day. At 10 weeks’ gestation, she was again diagnosed with gestational diabetes.

This patient had no history of weight gain or diabetes on olanzapine treatment (2.5 mg) prior to pregnancy or postpartum. However, the development of gestational diabetes in the latter half of her first pregnancy, new-onset hypertriglyceridemia and dyslipidemia postpregnancy, and recurrence of gestational diabetes in her second pregnancy are indicative of impaired glucose tolerance and insulin resistance.

Risk factors for the development of gestational diabetes include higher-than-normal body weight, maternal age > 25 years, non-Caucasian ethnicity, and family history of diabetes.2 Gestational diabetes has been associated with increased risk for recurrence in future pregnancies.3

This patient had risk factors for gestational diabetes, including age and Asian ethnicity. It is unclear if the abnormalities in glucose metabolism during pregnancy and postpartum were manifestations of underlying insulin resistance or were exacerbated by olanzapine. Elevated glucose values occurred after olanzapine dose increases, suggesting that olanzapine might have played an etiologic role. Future studies are needed to elucidate the relationship between medications and pregnancy in the development of impaired glucose tolerance.

Dr. Rasgon has received grant/research support from Abbott, Forest, GlaxoSmithKline, and Wyeth-Ayerst; is on the advisory boards for GlaxoSmithKline and Wyeth-Ayerst; and currently receives or has received speaker honoraria from Abbott, Bristol-Myers Squibb, Forest, GlaxoSmithKline, and Pfizer. Dr. Vemuri reports no financial affiliation or other relationship relevant to the subject of this letter.

REFERENCES


Mytilee P. Vemuri, M.D.
Natalie L. Rasgon, M.D., Ph.D.
Department of Psychiatry and Behavioral Sciences
Stanford University
Stanford, California

Correction

In the article “Teratogenicity and Anticonvulsants: Lessons From Neurology to Psychiatry” by Adele Casals Viguera, M.D., et al. (2007, Supplement 9, pp. 29–33), under “North American Antiepileptic Pregnancy Registry” on page 31, the observed prevalence of major malformations in a total of 564 children exposed to lamotrigine monotherapy was incorrectly reported from reference 16 as 5 cases (2.7%). The correct prevalence is 15 cases (2.7%). The online version of the article has been corrected.